GlassScriptPhysician profile
William J Shergy
NPI 1073531307
$114,604.53
in general payments reported to CMS, 2019-2025
42 companies · $2,772 in 2025
The $2,772 reported for 2025 was more than what 75% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70K · 2020: $11K · 2021: $16K · 2022: $7,167 · 2023: $5,073 · 2024: $3,219 · 2025: $2,772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,538 · Consulting Fee: $2,500 · Education: $26.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,537.54 |
| Consulting Fee | $2,500.00 |
| Education | $26.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $58,166.92 | 2019-2025 | Otezla, Evenity, Enbrel |
| Celgene Corporation | $18,897.44 | 2019 | |
| Janssen Scientific Affairs, LLC | $15,789.24 | 2019-2021 | |
| Abbvie INC. | $6,641.09 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $6,489.35 | 2019-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $2,248.09 | 2019-2025 | |
| Ucb, INC. | $1,133.00 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $1,005.47 | 2019-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $642.81 | 2019-2025 | Orencia |
| Genzyme Corporation | $529.44 | 2023-2025 | |
| Pfizer INC. | $499.67 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $401.10 | 2021-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $291.69 | 2022-2025 | Acthar |
| Genentech USA, INC. | $290.54 | 2019-2025 | Gazyva, Actemra |
| Horizon Therapeutics Plc | $277.59 | 2019-2022 |
Show all 38 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Shergy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.